{"bundle_type":"pith_open_graph_bundle","bundle_version":"1.0","pith_number":"pith:2026:U4JMPDCCJT3KIHHNIV2HINJXRG","short_pith_number":"pith:U4JMPDCC","canonical_record":{"source":{"id":"2607.04571","kind":"arxiv","version":1},"metadata":{"license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2026-07-06T00:46:37Z","cross_cats_sorted":[],"title_canon_sha256":"4209198352846163b9338551294ae07e58268624db6339f86ad5fc1c71283bb9","abstract_canon_sha256":"b88247089a9c40ab95fa69b434482e35033fcf51470f358a0d22bd493b80592b"},"schema_version":"1.0"},"canonical_sha256":"a712c78c424cf6a41ced457474353789aa7c7118cf89586173c84616e8c7cf82","source":{"kind":"arxiv","id":"2607.04571","version":1},"source_aliases":[{"alias_kind":"arxiv","alias_value":"2607.04571","created_at":"2026-07-07T02:19:25Z"},{"alias_kind":"arxiv_version","alias_value":"2607.04571v1","created_at":"2026-07-07T02:19:25Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2607.04571","created_at":"2026-07-07T02:19:25Z"},{"alias_kind":"pith_short_12","alias_value":"U4JMPDCCJT3K","created_at":"2026-07-07T02:19:25Z"},{"alias_kind":"pith_short_16","alias_value":"U4JMPDCCJT3KIHHN","created_at":"2026-07-07T02:19:25Z"},{"alias_kind":"pith_short_8","alias_value":"U4JMPDCC","created_at":"2026-07-07T02:19:25Z"}],"events":[{"event_type":"record_created","subject_pith_number":"pith:2026:U4JMPDCCJT3KIHHNIV2HINJXRG","target":"record","payload":{"canonical_record":{"source":{"id":"2607.04571","kind":"arxiv","version":1},"metadata":{"license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2026-07-06T00:46:37Z","cross_cats_sorted":[],"title_canon_sha256":"4209198352846163b9338551294ae07e58268624db6339f86ad5fc1c71283bb9","abstract_canon_sha256":"b88247089a9c40ab95fa69b434482e35033fcf51470f358a0d22bd493b80592b"},"schema_version":"1.0"},"canonical_sha256":"a712c78c424cf6a41ced457474353789aa7c7118cf89586173c84616e8c7cf82","receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-07-07T02:19:25.385058Z","signature_b64":"Iciq6Boh5HWdWc/iu+hBJquCoo88A9owGyIhqOPW3tSjAkXlzrb6v8YGltC16demhnUQ16fpNdCHtv57Tyv4BQ==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"a712c78c424cf6a41ced457474353789aa7c7118cf89586173c84616e8c7cf82","last_reissued_at":"2026-07-07T02:19:25.384363Z","signature_status":"signed_v1","first_computed_at":"2026-07-07T02:19:25.384363Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"source_kind":"arxiv","source_id":"2607.04571","source_version":1,"attestation_state":"computed"},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-07-07T02:19:25Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"kkgym4eLY9ANqPTeTcZgopp5RXoHyv9Jd97vtaamWCQxiHHKOT+M5eMN3xLRD26Bgc7jhXAmjDnkWD5pRVNzDg==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-08-09T12:02:44.877896Z"},"content_sha256":"c319ac37f84844e66356fba5189539037e0e020d531f741dd07e4538564f0f23","schema_version":"1.0","event_id":"sha256:c319ac37f84844e66356fba5189539037e0e020d531f741dd07e4538564f0f23"},{"event_type":"graph_snapshot","subject_pith_number":"pith:2026:U4JMPDCCJT3KIHHNIV2HINJXRG","target":"graph","payload":{"graph_snapshot":{"paper":{"title":"Likelihood-Ratio E-Value Monitoring for Benchmark-Based Decisions in Early-Phase Oncology Trials","license":"http://creativecommons.org/licenses/by/4.0/","headline":"","cross_cats":[],"primary_cat":"stat.ME","authors_text":"Masahiro Kojima","submitted_at":"2026-07-06T00:46:37Z","abstract_excerpt":"Early-phase oncology trials often require protocol-ready interim rules for deciding whether an experimental regimen shows sufficient activity relative to prespecified clinical benchmarks. Existing Bayesian optimal phase II designs provide calibrated count boundaries for such decisions, but evidence is quantified through posterior probabilities and sample-size-dependent cutoff functions. We propose calibrated e-value monitoring (CEVAM), a likelihood-ratio evidence framework that defines monitoring evidence directly relative to prespecified clinical benchmarks, without requiring a Bayesian analy"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2607.04571","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"integrity":{"clean":true,"summary":{"advisory":0,"critical":0,"by_detector":{},"informational":0},"endpoint":"/pith/2607.04571/integrity.json","findings":[],"available":true,"detectors_run":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938"},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"verdict_id":null},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-07-07T02:19:25Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"YXJvNvXoo0gSldTpH+8Jt7INyB8xxhaL8X+jtt9oC3OJmKaoqNcSShLDF/+deehzG8aD+bVHTlVXvqsrkwD2CQ==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-08-09T12:02:44.878446Z"},"content_sha256":"e5075d524d19aa78138bae1f71a9ed1c93d0f625fac9ba16e4e0cc477e1929e2","schema_version":"1.0","event_id":"sha256:e5075d524d19aa78138bae1f71a9ed1c93d0f625fac9ba16e4e0cc477e1929e2"}],"timestamp_proofs":[],"mirror_hints":[{"mirror_type":"https","name":"Pith Resolver","base_url":"https://pith.science","bundle_url":"https://pith.science/pith/U4JMPDCCJT3KIHHNIV2HINJXRG/bundle.json","state_url":"https://pith.science/pith/U4JMPDCCJT3KIHHNIV2HINJXRG/state.json","well_known_bundle_url":"https://pith.science/.well-known/pith/U4JMPDCCJT3KIHHNIV2HINJXRG/bundle.json","status":"primary"}],"public_keys":[{"key_id":"pith-v1-2026-05","algorithm":"ed25519","format":"raw","public_key_b64":"stVStoiQhXFxp4s2pdzPNoqVNBMojDU/fJ2db5S3CbM=","public_key_hex":"b2d552b68890857171a78b36a5dccf368a953413288c353f7c9d9d6f94b709b3","fingerprint_sha256_b32_first128bits":"RVFV5Z2OI2J3ZUO7ERDEBCYNKS","fingerprint_sha256_hex":"8d4b5ee74e4693bcd1df2446408b0d54","rotates_at":null,"url":"https://pith.science/pith-signing-key.json","notes":"Pith uses this Ed25519 key to sign canonical record SHA-256 digests. Verify with: ed25519_verify(public_key, message=canonical_sha256_bytes, signature=base64decode(signature_b64))."}],"merge_version":"pith-open-graph-merge-v1","built_at":"2026-08-09T12:02:44Z","links":{"resolver":"https://pith.science/pith/U4JMPDCCJT3KIHHNIV2HINJXRG","bundle":"https://pith.science/pith/U4JMPDCCJT3KIHHNIV2HINJXRG/bundle.json","state":"https://pith.science/pith/U4JMPDCCJT3KIHHNIV2HINJXRG/state.json","well_known_bundle":"https://pith.science/.well-known/pith/U4JMPDCCJT3KIHHNIV2HINJXRG/bundle.json"},"state":{"state_type":"pith_open_graph_state","state_version":"1.0","pith_number":"pith:2026:U4JMPDCCJT3KIHHNIV2HINJXRG","merge_version":"pith-open-graph-merge-v1","event_count":2,"valid_event_count":2,"invalid_event_count":0,"equivocation_count":0,"current":{"canonical_record":{"metadata":{"abstract_canon_sha256":"b88247089a9c40ab95fa69b434482e35033fcf51470f358a0d22bd493b80592b","cross_cats_sorted":[],"license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2026-07-06T00:46:37Z","title_canon_sha256":"4209198352846163b9338551294ae07e58268624db6339f86ad5fc1c71283bb9"},"schema_version":"1.0","source":{"id":"2607.04571","kind":"arxiv","version":1}},"source_aliases":[{"alias_kind":"arxiv","alias_value":"2607.04571","created_at":"2026-07-07T02:19:25Z"},{"alias_kind":"arxiv_version","alias_value":"2607.04571v1","created_at":"2026-07-07T02:19:25Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2607.04571","created_at":"2026-07-07T02:19:25Z"},{"alias_kind":"pith_short_12","alias_value":"U4JMPDCCJT3K","created_at":"2026-07-07T02:19:25Z"},{"alias_kind":"pith_short_16","alias_value":"U4JMPDCCJT3KIHHN","created_at":"2026-07-07T02:19:25Z"},{"alias_kind":"pith_short_8","alias_value":"U4JMPDCC","created_at":"2026-07-07T02:19:25Z"}],"graph_snapshots":[{"event_id":"sha256:e5075d524d19aa78138bae1f71a9ed1c93d0f625fac9ba16e4e0cc477e1929e2","target":"graph","created_at":"2026-07-07T02:19:25Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"graph_snapshot":{"author_claims":{"count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","strong_count":0},"builder_version":"pith-number-builder-2026-05-17-v1","claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"integrity":{"available":true,"clean":true,"detectors_run":[],"endpoint":"/pith/2607.04571/integrity.json","findings":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938","summary":{"advisory":0,"by_detector":{},"critical":0,"informational":0}},"paper":{"abstract_excerpt":"Early-phase oncology trials often require protocol-ready interim rules for deciding whether an experimental regimen shows sufficient activity relative to prespecified clinical benchmarks. Existing Bayesian optimal phase II designs provide calibrated count boundaries for such decisions, but evidence is quantified through posterior probabilities and sample-size-dependent cutoff functions. We propose calibrated e-value monitoring (CEVAM), a likelihood-ratio evidence framework that defines monitoring evidence directly relative to prespecified clinical benchmarks, without requiring a Bayesian analy","authors_text":"Masahiro Kojima","cross_cats":[],"headline":"","license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2026-07-06T00:46:37Z","title":"Likelihood-Ratio E-Value Monitoring for Benchmark-Based Decisions in Early-Phase Oncology Trials"},"references":{"count":0,"internal_anchors":0,"resolved_work":0,"sample":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2607.04571","kind":"arxiv","version":1},"verdict":{"created_at":null,"id":null,"model_set":{},"one_line_summary":"","pipeline_version":null,"pith_extraction_headline":"","strongest_claim":"","weakest_assumption":""}},"verdict_id":null}}],"author_attestations":[],"timestamp_anchors":[],"storage_attestations":[],"citation_signatures":[],"replication_records":[],"corrections":[],"mirror_hints":[],"record_created":{"event_id":"sha256:c319ac37f84844e66356fba5189539037e0e020d531f741dd07e4538564f0f23","target":"record","created_at":"2026-07-07T02:19:25Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"attestation_state":"computed","canonical_record":{"metadata":{"abstract_canon_sha256":"b88247089a9c40ab95fa69b434482e35033fcf51470f358a0d22bd493b80592b","cross_cats_sorted":[],"license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2026-07-06T00:46:37Z","title_canon_sha256":"4209198352846163b9338551294ae07e58268624db6339f86ad5fc1c71283bb9"},"schema_version":"1.0","source":{"id":"2607.04571","kind":"arxiv","version":1}},"canonical_sha256":"a712c78c424cf6a41ced457474353789aa7c7118cf89586173c84616e8c7cf82","receipt":{"algorithm":"ed25519","builder_version":"pith-number-builder-2026-05-17-v1","canonical_sha256":"a712c78c424cf6a41ced457474353789aa7c7118cf89586173c84616e8c7cf82","first_computed_at":"2026-07-07T02:19:25.384363Z","key_id":"pith-v1-2026-05","kind":"pith_receipt","last_reissued_at":"2026-07-07T02:19:25.384363Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","receipt_version":"0.3","signature_b64":"Iciq6Boh5HWdWc/iu+hBJquCoo88A9owGyIhqOPW3tSjAkXlzrb6v8YGltC16demhnUQ16fpNdCHtv57Tyv4BQ==","signature_status":"signed_v1","signed_at":"2026-07-07T02:19:25.385058Z","signed_message":"canonical_sha256_bytes"},"source_id":"2607.04571","source_kind":"arxiv","source_version":1}}},"equivocations":[],"invalid_events":[],"applied_event_ids":["sha256:c319ac37f84844e66356fba5189539037e0e020d531f741dd07e4538564f0f23","sha256:e5075d524d19aa78138bae1f71a9ed1c93d0f625fac9ba16e4e0cc477e1929e2"],"state_sha256":"e30fd1eed196beb935000cba9ea9531d6d7f95138ea63b93c18a573c1454cc01"},"bundle_signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"nPFJg2PtTex5odtPjEa7UAfHwr1OP3y7aIoNu/6Z5Cbjy4LvgI0CNDcBNrdnwH0/4zEK9SW472axi8s6uNO9Cw==","signed_message":"bundle_sha256_bytes","signed_at":"2026-08-09T12:02:44.883165Z","bundle_sha256":"4039f26aa46bff42f8d61c33242b7d1cca8e735dbbcd5ee0566f066051299c74"}}